Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia
Publication
, Conference
Margolis, DM; James, KS; Tuyishime, M; Falcinelli, SD; Joseph, SB; Allard, B; Kirchherr, JL; Clohosey, M; Gorelick, RJ; Gama, L; Koup, RA ...
Published in: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2021
Duke Scholars
Published In
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
EISSN
1758-2652
Publication Date
2021
Volume
24
Start / End Page
69 / 69
Related Subject Headings
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Margolis, D. M., James, K. S., Tuyishime, M., Falcinelli, S. D., Joseph, S. B., Allard, B., … Gay, C. L. (2021). Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 24, pp. 69–69).
Margolis, D. M., K. S. James, M. Tuyishime, S. D. Falcinelli, S. B. Joseph, B. Allard, J. L. Kirchherr, et al. “Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 24:69–69, 2021.
Margolis DM, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Allard B, et al. Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2021. p. 69–69.
Margolis, D. M., et al. “Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 24, 2021, pp. 69–69.
Margolis DM, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Allard B, Kirchherr JL, Clohosey M, Gorelick RJ, Gama L, Koup RA, Mascola JR, Floris-Moore M, Ferrari G, Eron JJ, Kuruc JD, Archin NM, Gay CL. Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2021. p. 69–69.
Published In
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
EISSN
1758-2652
Publication Date
2021
Volume
24
Start / End Page
69 / 69
Related Subject Headings
- 4206 Public health
- 4202 Epidemiology
- 3202 Clinical sciences
- 1199 Other Medical and Health Sciences
- 1117 Public Health and Health Services
- 1103 Clinical Sciences